EGFR and neoplasm: Bispecific γδ T cell engager is being developed, the antibody targeting Vγ9Vδ2 on γδ T cells and EGFR on tumors cells was demonstrated to induce strong activation of Vγ9Vδ2 T cells and cytotoxic lysis of tumor cells in a mouse xenograft model [171].